Management of Albumin Therapy in Hepatorenal Syndrome with Anasarca

Rationale for Discontinuing Albumin in Anasarca

Albumin administration is primarily beneficial in specific clinical scenarios for patients with liver disease, but has limited utility in the management of refractory ascites once anasarca develops 1, 2
The American Association for the Study of Liver Diseases guidelines indicate insufficient data to recommend long-term use of albumin infusions outside the setting of large-volume paracentesis in patients with refractory ascites 1
When severe peripheral edema (anasarca) develops, it indicates significant fluid overload that will not be effectively managed with continued albumin administration 2

Prevention of post-paracentesis circulatory dysfunction during large-volume paracentesis (>5L) at a dose of 6-8g per liter of ascites removed 1, 3
Prevention of renal failure in spontaneous bacterial peritonitis 2, 4
Initial management of hepatorenal syndrome with vasoconstrictors (terlipressin, noradrenaline) at a dose of 1g/kg on day 1 (maximum 100g) followed by 20-40g/day 5, 6

Assess volume status and severity of anasarca, documenting extent of peripheral edema, ascites, and pleural effusions, and monitoring daily weights and fluid balance 2, 3
Discontinue albumin therapy when anasarca develops 1, 2
Implement alternative management strategies, including continuing vasoconstrictors (terlipressin or noradrenaline) without albumin, considering diuretic therapy for volume overload management, and maintaining sodium restriction (<2g/day) 1, 2, 4, 5, 6

Albumin discontinuation should not affect the continued use of vasoconstrictors (terlipressin or noradrenaline) for hepatorenal syndrome management 5, 6
Avoid excessive fluid restriction in patients with hyponatremia; limit fluid intake to <1000mL/day only if serum sodium <125 mEq/L 1
Monitor for worsening renal function after albumin discontinuation and adjust management accordingly 5, 6
The development of anasarca in hepatorenal syndrome indicates poor prognosis and should prompt urgent consideration for liver transplantation 5, 6

The recommendation to discontinue albumin in anasarca is based on expert opinion and clinical practice guidelines rather than randomized controlled trials 1, 2
The evidence for albumin use in specific scenarios (paracentesis, spontaneous bacterial peritonitis) is stronger than for its continued use in anasarca 1, 3

Vasoconstrictor therapy, including octreotide with midodrine or norepinephrine, should be maintained even when albumin is discontinued due to volume overload complications, as recommended by the American Society of Transplantation 7
Octreotide in combination with midodrine works by reducing splanchnic vasodilation and improving effective arterial blood volume, which is a key mechanism in hepatorenal syndrome pathophysiology, according to the American Association for the Study of Liver Diseases 8
Octreotide should be continued at 200 μg subcutaneously three times daily, and if using midodrine with octreotide, midodrine should be continued at up to 12.5 mg orally three times daily, as suggested by the American Society of Transplantation 7
Norepinephrine should be continued at 0.5-3.0 mg/h to maintain increased mean arterial pressure, as recommended by the American Society of Transplantation 7

Terlipressin plus albumin is the first-line treatment for hepatorenal syndrome where available, with a response rate of approximately 35-45%, according to the American Association for the Study of Liver Diseases 9
Renal replacement therapy should be considered in patients with worsening kidney function, fluid overload despite diuretic therapy, or problematic acid-base status, as suggested by the American Society of Transplantation 7
TIPS (transjugular intrahepatic portosystemic shunt) may be considered in selected patients with lower MELD scores, as recommended by the American Society of Transplantation 7
Liver transplantation remains the definitive treatment for hepatorenal syndrome and should be expedited when possible, according to the American Society of Transplantation 7